Loading clinical trials...
Loading clinical trials...
Phase 1/2, Open-label Study Evaluating Safety of Repeat Administration of Ad/PNP-F-araAMP (Ad/PNP Administered Intratumorally Followed by Intravenous Fludarabine Phosphate) in Subjects With Recurrent, Local Head and Neck Cancer
Conditions
Interventions
Ad/PNP
Fludarabine Phosphate
Locations
3
United States
Stanford University
Stanford, California, United States
Winship Cancer Institute - Emory University School of Medicine
Atlanta, Georgia, United States
Thomas Jefferson University
Philadelphia, Pennsylvania, United States
Start Date
February 11, 2019
Primary Completion Date
December 29, 2023
Completion Date
December 31, 2024
Last Updated
March 27, 2025
NCT05980000
NCT02358031
NCT03991741
NCT03691714
NCT04969861
NCT00088907
Lead Sponsor
GeoVax, Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions